Literature DB >> 14748735

Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer's disease.

A V Alessenko1, A E Bugrova, L B Dudnik.   

Abstract

Alzheimer's disease (AD) is characterized by progressive decline in cognition, memory and intellect. It has been hypothesized that amyloid-beta peptide (A-beta) may have a prominent role in neurodegeneration. Oxidative mechanisms have been implicated in this pathway. There is substantial evidence that inflammatory mechanisms, induced by tumour necrosis factor alpha (TNF-alpha), are also involved in AD. TNF-alpha activates receptors linked to multiple effector systems, including a sphingomyelin pathway and peroxide oxidation. We have determined the changes of neutral sphingomyelinase activity, sphingomyelin and ceramide contents, and the level of lipid peroxide products (conjugated dienes), in the cerebral cortex, hippocampus and cerebellum of rats within 3 h and 7 days of intracerebral injection of A-beta and TNF-alpha. A single injection of A-beta and TNF-alpha has been shown to increase the level of peroxide products in the hippocampus and cerebral cortex within 3 h and 7 days. Sphingomyelinase activity and ceramide levels have been found to increase 7 days after A-beta administration. We found that activation of the sphingomyelin pathway lies downstream from the oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14748735     DOI: 10.1042/bst0320144

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  33 in total

1.  Sphingosine kinase-1 protects differentiated N2a cells against beta-amyloid25-35-induced neurotoxicity via the mitochondrial pathway.

Authors:  Yang Yang; Min Wang; Bingjie Lv; Rong Ma; Jing Hu; Yaoyan Dun; Shenggang Sun; Gang Li
Journal:  Neurochem Res       Date:  2014-03-30       Impact factor: 3.996

Review 2.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

3.  Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes.

Authors:  Maria F Lopes-Virella; Nathaniel L Baker; Kelly J Hunt; Samar M Hammad; John Arthur; Gabriel Virella; Richard L Klein
Journal:  J Clin Lipidol       Date:  2019-04-03       Impact factor: 4.766

Review 4.  Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.

Authors:  Marcus O W Grimm; Daniel M Michaelson; Tobias Hartmann
Journal:  J Lipid Res       Date:  2017-05-20       Impact factor: 5.922

Review 5.  Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases.

Authors:  S M De La Monte
Journal:  Panminerva Med       Date:  2012-09       Impact factor: 5.197

6.  Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease.

Authors:  Ming Tong; Alexander Neusner; Lisa Longato; Margot Lawton; Jack R Wands; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 7.  Relationships between diabetes and cognitive impairment.

Authors:  Suzanne M de la Monte
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

Review 8.  Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death.

Authors:  Arundhati Jana; Edward L Hogan; Kalipada Pahan
Journal:  J Neurol Sci       Date:  2009-01-14       Impact factor: 3.181

Review 9.  Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Lisa Longato; Ming Tong; Jack R Wands
Journal:  Curr Opin Investig Drugs       Date:  2009-10

10.  Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment.

Authors:  Suzanne M de la Monte; Ming Tong; Margot Lawton; Lisa Longato
Journal:  Mol Neurodegener       Date:  2009-12-24       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.